Evaluation of Drug Vulnerability of NF2 Tumor Models

Email Principal Investigator
Planning
Specimen
Asset 20.png
Joe Kissil

Joseph Kissil

Moffitt Cancer Center
Tampa, FL, USA

CBTN Specimen

Backer

Internal funding

About this

Project

NF2 tumors are very rare and understudied tumors. An important part of studying tumors is understanding how drugs interact with them. This proposal aims to explore 3000+ compounds on NF2 cell lines, samples derived from patients with NF2 tumors. Exploring the interactions of drugs with the tumor can highlight opportunities for new treatments. Part of the challenge in studying NF2 tumors is the availability of high quality specimens. There are very few cell lines available for use by researchers, making specimens made available through the Pediatric Brain Tumor Atlas invaluable to this work. The generated data may be the first of the type in the field and will establish drug vulnerability as well as potential targets/biomarkers specific to the NF2 tumors. The data generated from this study will help guide continued study of NF2 tumors and support the identification of new therapies.

Ask The

Scientists

Ask the scientists

What are the goals of this project?

The goal of this project is to explore how over 3000 compounds interact with NF2 cell lines in an effort to identify new therapies.

What is the impact of this project?

This project will generate data that could be used in the pursuit of new NF2 therapeutics as well as establishing drug vulnerability and highlighting potential targets specific to this tumor type.

Why is the CBTN request important to this project?

This research requires high quality specimens, which are rare especially for this tumor type. The Children’s Brain Tumor network is therefore an invaluable resource to this work.